NCT06341478View on ClinicalTrials.gov

Investigator Grant (IG) 2022 27746

NARecruitingINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

March 15, 2026

Study Completion Date

March 15, 2027

Conditions
Bladder Cancer
Interventions
DRUG

various neoadjuvant therapies

Radical cystectomy, Sacituzumab Govitecan (SG), SG + pembrolizumab, nivolumab+abraxane

Trial Locations (1)

20132

RECRUITING

IRCCS Ospedale San Raffaele, Milan

All Listed Sponsors
lead

IRCCS San Raffaele

OTHER